Center on Health Equity & Access

Emily Curran, MD, University of Cincinnati, calls for decentralized trials and stronger community-academic ties to widen ALL patient access.

Hospital-at-home meets inpatient safety, PBM insulin settlement lowers costs, SNAP narrows screening gaps, and execs warn innovation outpaces reimbursement.

An analysis found no significant differences in care escalation, readmission, mortality, or guideline-directed therapy use between home-based and inpatient care.

FTC settles with CVS Caremark over insulin pricing, projecting $8.5 billion in patient savings over 10 years and mandating rebate and access reforms.

SNAP participation was linked to a smaller colorectal cancer screening gap among food-insecure US adults, ananalysis of 251,000 found.

Health system executives say Medicaid cuts, payer disputes, and misaligned incentives are driving the affordability crisis in 2026.

Kerry Rogers, MD, at The James, unpacks what these questions mean for patient counseling and clinical trial equity in chronic lymphocytic leukemia (CLL).

New topicals, orals, and biologics are expanding chronic hand eczema treatment, but phenotype-specific data gaps remain.

CMS's enforcement surge has put every Medicaid Fraud Control Unit under review, but experts say the bigger driver of coverage loss may be red tape.

June author Erin L. Duffy, PhD, MPH, discusses her study showing nonprofit and system-affiliated hospitals provide greater access to translated financial assistance documents.

Medicare Advantage (MA) beneficiaries had similar optimal cancer treatment use and treatment timing as traditional Medicare (TM), with lower anticipated costs.

Robert Kratzke, MD, discusses how biomarker testing mandates and faster sequencing can improve access to precision lung cancer care.

Pharmacy eases lung cancer costs; pediatric cancer erases 40% income; BTKis widen CLL access; hospitals lag on translated aid; MN mandate ends NGS denials.

Stefanie Houseknecht, PharmD, discusses patient education, financial barriers, and pharmacy's expanding role in precision lung cancer care.

Financial toxicity in pediatric cancer extends beyond medical bills, affecting treatment adherence, caregivers, and survivors long-term, Cherie Daly, MD, said.

Erin L. Duffy, PhD, MPH, discusses her findings that nonprofit and system-affiliated hospitals have better multilingual access to financial aid documents.

Bhavana Bhatnagar, DO, who moved from academic to community oncology, shares why stronger academic-community partnerships are essential for patient care.

In a cross-sectional study of US hospitals, patient financial assistance and billing policy documents averaged 10th-grade readability scores, with variation significantly associated with several attributes.

Racial gaps in cancer pain care; CGT program reimbursement hurdles; FIB4 liver screening underused; OCM legacy debated; MM bispecifics face access gaps.

Real-world data show patients with MASH reach cirrhosis in just 16 months, fueling calls for wider use of fibrosis biomarkers like FIB-4.

A meta-analysis of 39 studies found similar or slightly better cancer survival for Black veterans compared with White veterans in the VHA.

The Pediatric Cancer Research Foundation calls for systemic change as pediatric cancer creates long-term financial burdens extending through survivorship.

Real-world data reveal racial disparities in cancer pain medication timing and strong opioid prescribing, with gaps most pronounced in breast and prostate cancer.

FIB4 testing can catch liver disease early, but Naim Alkhouri, MD, and Chika Anekwe, MD, say it remains underused in obesity and primary care.

Senate Democrats introduced a bill to cap out-of-pocket costs at $5000 for traditional Medicare beneficiaries and expand low-income assistance.